<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04674111</url>
  </required_header>
  <id_info>
    <org_study_id>S2465</org_study_id>
    <nct_id>NCT04674111</nct_id>
  </id_info>
  <brief_title>Vortex - Temporary Percutaneous, Transvalvular Circulatory Support System Feasibility Study</brief_title>
  <acronym>Vortex-FIH</acronym>
  <official_title>Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vortex - First in Human study to evaluate the feasibility, safety, clinical and technical&#xD;
      success of the Vortex temporary percutaneous, transvalvular circulatory support system&#xD;
      (Vortex System)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 28, 2021</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Prospective, open-label, single-arm feasibility study</intervention_model_description>
    <primary_purpose>Device Feasibility</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>The Vortex system is indicated to provide temporary (≤ 4 hours) circulatory intended to be used to support in patients undergoing high-risk percutaneous coronary intervention (HR PCI).</time_frame>
    <description>Successful delivery of the device to the correct anatomical position and successful operation and removal of the Vortex circulatory support system</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical success</measure>
    <time_frame>The Vortex system is indicated to provide temporary (≤ 4 hours) circulatory intended to be used to support in patients undergoing high-risk percutaneous coronary intervention (HR PCI).</time_frame>
    <description>No conversion to open heart surgery; and no in-hospital mortality</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Vortex Feasibility Study (Vortex FIH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vortex - First in Human Study to Evaluate the Feasibility, Safety, Clinical and Technical Success of the Vortex Temporary Percutaneous, Transvalvular Circulatory Support System (Vortex System)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Temporary Percutaneous Transvalvular Circulatory Support System (Vortex System)</intervention_name>
    <description>The Vortex System is indicated to provide temporary circulatory support in subjects undergoing elective high-risk percutaneous coronary intervention (HR-PCI).</description>
    <arm_group_label>Vortex Feasibility Study (Vortex FIH)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        A subject will be considered for enrolment in the study if all of the following inclusion&#xD;
        criteria are met, provided no exclusion criteria are met:&#xD;
&#xD;
        IC1. Subject provides signed informed consent. IC2. Subject is ≥ 18 years and &lt; 90 years of&#xD;
        age.&#xD;
&#xD;
        IC3 Subject is indicated for NON-emergent PCI of at least one de novo or restenotic lesion&#xD;
        in a native coronary vessel or coronary artery bypass graft (CABG) and has left ventricular&#xD;
        ejection fraction (LVEF) ≤ 50% with the following:&#xD;
&#xD;
          -  Unprotected left main -OR-&#xD;
&#xD;
          -  Last remaining vessel -OR-&#xD;
&#xD;
          -  Three vessel disease (≥ 50% diameter stenoses by visual estimate or total occlusion)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A subject will be excluded from the study if any of the following exclusion criteria are&#xD;
        met:&#xD;
&#xD;
        EC1. Subject has had ST-elevation myocardial infarction (STEMI) within 24 hours.&#xD;
&#xD;
        EC2. Subject has had pre-procedure cardiac arrest requiring cardiopulmonary resuscitation&#xD;
        (CPR) within 24 hours of enrollment.&#xD;
&#xD;
        EC3. Subject is in shock, defined as follows:&#xD;
&#xD;
          -  Cardiac index (CI) &lt; 2.2 L/min/m2 and pulmonary capillary wedge pressure (PCWP) &gt; 15&#xD;
             mmHg -AND-&#xD;
&#xD;
          -  Hypotension (systolic blood pressure &lt; 90 mmHg for &gt; 30 minutes) -OR-&#xD;
&#xD;
          -  Need for supportive measures (i.e., inotropes or mechanical support) to maintain&#xD;
             systolic blood pressure ≥ 90 mmHg and end organ hypoperfusion (cool extremities or&#xD;
             urine &lt; 30 mL/hour and a heart rate &gt; 60 beats per minute) EC4. Subject has left&#xD;
             ventricular mural thrombus. EC5. Subject has a prosthetic aortic valve. EC6. Subject&#xD;
             has pericarditis or constrictive heart disease (constrictive pericarditis or&#xD;
             restrictive cardiomyopathy).&#xD;
&#xD;
        EC7. Subject has moderate or greater aortic valve stenosis or moderate or greater aortic&#xD;
        valve insufficiency (by echocardiographic assessment, graded as ≥ 2+).&#xD;
&#xD;
        EC8. Subject has abnormalities of the aorta that preclude safe delivery of the device,&#xD;
        including severe calcification, tortuosity, aneurysm, or prior surgery.&#xD;
&#xD;
        EC9. Subject has peripheral vessel disease (PVD) preventing passage of the device (e.g.,&#xD;
        calcification, small caliber) or tortuosity that would preclude safe placement of the 16 Fr&#xD;
        introducer sheath.&#xD;
&#xD;
        Note: Minimum required vessel diameter is &gt; 5.5 mm. EC10. Subject has advanced renal&#xD;
        dysfunction (AKIN Stage 3). EC11. Subject has a history of liver dysfunction (Childs Class&#xD;
        C) with elevation of liver enzymes and bilirubin &gt; 3× upper limit of normal (ULN) or&#xD;
        international normalization ratio (INR) ≥ 2.&#xD;
&#xD;
        EC12. Subject has had a recent (within 1 month) stroke or TIA. EC13. Subject has known&#xD;
        hypersensitivity to intravenous contrast agents that cannot be adequately pre-medicated or&#xD;
        has known hypersensitivity to heparin, aspirin, ADP receptor inhibitors or nitinol.&#xD;
&#xD;
        EC14. Subject has current or a history of heparin induced thrombocytopenia (HIT).&#xD;
&#xD;
        EC15. Subject has uncorrected abnormal coagulation or platelet count ≤ 75,000/mm³ or INR ≥&#xD;
        2.0.&#xD;
&#xD;
        EC16. Subject has significant right heart failure (right atrial pressure [RAP] &gt; 15 mmHg,&#xD;
        right ventricular stroke work index [RVSWI] &lt; 0.30 mmHg·L/m², pulmonary vascular resistance&#xD;
        [PVR] &gt; 3.6 Woods units).&#xD;
&#xD;
        EC17. Subject requires mechanical ventilation. EC18. Subject has an atrial or ventricular&#xD;
        septal defect (including post-infarct ventricular septal defect [VSD]).&#xD;
&#xD;
        EC19. Subject has left ventricular rupture. EC20. Subject has cardiac tamponade. EC21.&#xD;
        Subject has severe pulmonary disease (FEV1 &lt; 1L). EC22. Subject has sustained or&#xD;
        non-sustained ventricular tachycardia. EC23. Subject is breast feeding or is pregnant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Antony Walton, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Alfred</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Maurer</last_name>
    <phone>800-876-9960</phone>
    <email>amy.maurer@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arjun Bhat, MBBS, MBA</last_name>
    <phone>800-876-9960</phone>
    <email>arjun.bhat@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Prof. Antony Walton, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>222-42</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Matthias Gotberg, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 14, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mechanical circulatory support</keyword>
  <keyword>High risk percutaneous coronary intervention (HR PCI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

